Promising Data for Fulgent Genetics' FID-007 in Head and Neck Cancer

By Chris Stiles • Tuesday, June 02 09:54 • Permanent Link

Fulgent Genetics said updated phase 2 data for fid-007 in combination with cetuximab showed an objective response rate of 61.9% in patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease had progressed after PD-1–based therapy.

The company said median progression-free survival was 6.7 months, median duration of response was 7.4 months, and one-year overall survival was 63.4% as of the April 16, 2026 data cutoff.

The study is testing two dosing regimens in an open-label, randomized phase 2 trial. Fulgent said the combination showed activity in both HPV-related and HPV-unrelated disease, and that the safety profile was manageable.

The company said a phase 3 study is planned. Following these announcements, the company's shares moved 0.66%, and are now trading at a price of $18.26. For the full picture, make sure to review Fulgent Genetics's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.